
    
      Primary Purpose: This study is designed to demonstrate the bioequivalence of Saxagliptin and
      Dapagliflozin from a FDC tablet after oral administration relative to Saxagliptin and
      Dapagliflozin tablets administered orally together in the fasted and fed state
    
  